Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating income | -$39.9M | -$82.4M | -$156M |
| Net income | -$52.0M | -$68.0M | -$138M |
| EPS (diluted) | -$89.61 | -$4.05 | -$2.52 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$45.6M | -$74.8M | -$107M |
| Capital expenditures | $586K | $71.0K | $280K |
| Free cash flow | -$46.2M | -$74.8M | -$107M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $230M | $490M | $96.7M |
| Total assets | $234M | $510M | $431M |
| Total liabilities | $15.5M | $18.1M | $29.5M |
| Shareholders' equity | -$149M | $492M | $401M |
| Retained earnings | -$153M | -$221M | -$359M |
| Shares (wtd avg diluted) | 580M | 16.8B | 54.7B |
Every figure is extracted from Bicara Therapeutics Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.